As described by Galie et al., Macitentan showed improved outcomes compared to placebo in both 3 mg and 10 mg doses regarding mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), and NT-proBNP levels regardless of WHO FC and background PAH-specific therapy [26]. This evidence concerns the gene NPPB and pulmonary arterial hypertension.